PDCD1 and melanoma: In brief, all the results above are consistent with the treatment outcomes of advanced cases, suggesting the poor prognostic immune features of the tumor microenvironment as well as compromised efficacy of adjuvant anti-PD-1 therapy in melanoma (especially the acral subtype).